Obagi Medical Products, Inc.’ New Study Shows CLENZIderm M.D. is Clinically Effective in the Treatment of Acne at Both Once- and Twice-Daily Dosing

LONG BEACH, Calif.--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today highlights from a clinical evaluation of its novel CLENZIderm M.D. Acne Therapeutic System at the Summer Meeting of the American Academy of Dermatology (AAD) taking place in New York, August 1-5.